DPP4 and metabolic dysfunction-associated steatotic liver disease: Incretin modulators, including agents from both the glucagon-like peptide-1 (GLP-1) agonist and dipeptidyl peptidase-4 (DPP-4) inhibitor classes, have recently shown promise in potentially reducing the progression of NAFLD.